MSA
DNTH icon

Marino Stram & Associates’s Dianthus Therapeutics DNTH Stock Holding History

Marino Stram & Associates’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-102
Closed -$27K – 202
2019
Q1 		$27K Hold
102
– – 0.02% 213
2018
Q4 		$9K Hold
102
– – 0.01% 285
2018
Q3 		$20K Buy
+102
New +$21.5K 0.02% 245
2018
Q2 		– Hold
0
– – – 232

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Marino Stram & Associates's DNTH Position: Q2 2019 in Review

Marino Stram & Associates sold out of Dianthus Therapeutics (DNTH) in Q2 2019, closing a stake of 102 shares — an estimated $27K sold.

Marino Stram & Associates first reported a position in DNTH in Q3 2018 and held it in 3 quarters. The position peaked at $27K in Q1 2019. 70 funds tracked by Wall St. Rank hold DNTH as of Q2 2019.

  • Marino Stram & Associates reported no remaining Dianthus Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Marino Stram & Associates sold 102 Dianthus Therapeutics shares in Q2 2019, an estimated $27K.
  • Marino Stram & Associates first reported a position in Dianthus Therapeutics in Q3 2018 and held it in 3 quarters.
  • Marino Stram & Associates's Dianthus Therapeutics position peaked at $27K in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2019.

Based on Marino Stram & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.